From: Guideline-based management of acute respiratory failure and acute respiratory distress syndrome
 | JRS/JSICM/JSRCM-GL2021 | SSCG2021 | SRLF-GL 2019 | FICM/ICS- GL 2018 | SSAI-ARDS-GL2016 | KSCCM/KATRD-ARDS-GL2016 | CIRCI-GL2017 |
---|---|---|---|---|---|---|---|
Restrictive fluid management | B | Â | Â | B | B | Â | Â |
Pharmacotherapy | Â | Â | Â | Â | Â | Â | Â |
Corticosteroids | A (1–2 mg/kg) |  |  | C | E | D | B |
Neutrophil elastase inhibitor | D |  |  |  |  |  |  |
Beta2-agonists | E | Â | Â | Â | E | Â | Â |
NO inhalation | D | Â | C | D | E | E | Â |
Thrombomodulin | – |  |  |  |  |  |  |
ECMO | B: Severe | B: V-V, severe | A: V-V | B: Severe | Â | B | Â |
Early rehabilitation | B: ≤ 72 h |  |  |  |  |  |  |
No or light sedation | B | Â | Â | Â | Â | A | Â |
Omega-3 fatty acids enteral nutrition | B | Â | Â | Â | Â | Â | Â |